Background Idiopathic pulmonary fibrosis (IPF) is a debilitating condition with significant
morbidity and poor survival. Since 2010, there has been increased activity in the …

Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung
disease presenting in persons 50 years and older. Through a comprehensive review of …

Background: Patients with idiopathic pulmonary fibrosis (IPF) often do not tolerate
pirfenidone in the recommended dose of 2400 mg/day. The proportion of patients requiring …

Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a median survival of
approximately three years in historical cohorts. Despite increased knowledge of disease …

Medical therapy for idiopathic fibrosis remains controversial. Idiopathic pulmonary fibrosis
(IPF) was uniformly a disease that progressed inexorably, typically leading to death within 3 …

OBJECTIVE: The incidence of idiopathic pulmonary fibrosis is increasing year by year in the
world, which has a greater impact on the quality of life of patients. In the past, symptomatic …

Children's interstitial and diffuse lung disease (chILD) is a term that encompasses a large
and diverse group of rare pediatric diseases and disorders. Significant progress has been …

Mucin-1 is a multi-functional glycoprotein expressed by type II alveolocytes and may be
detectable in the circulation following pulmonary fibrosis. The prognostic utility of baseline …

Background: 6MWT is simple, easy to perform, highly reproducible test. Its precise indication
is to assess the response to therapy in various chronic lung disorders. High cost and …

Introduction: Pirfenidone is a novel oral anti-fibrotic agent approved for the treatment of
idiopathic pulmonary fibrosis (IPF). Since IPF is a chronic and progressive disease most …